.jpg "Halozyme (NASDAQ: HALO)")
In a report released yesterday, Jason Butler from JMP Securities maintained a Buy rating on Halozyme (HALO), with a price target of $21. The company’s shares closed yesterday at $17.18.
According to TipRanks.com, Butler is a 5-star analyst with an average return of 15.6% and a 52.2% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Axovant Gene Therapies, and Neos Therapeutics.
Currently, the analyst consensus on Halozyme is a Moderate Buy with an average price target of $21, representing a 22.2% upside. In a report issued on February 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
Based on Halozyme’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.13 million. In comparison, last year the company had a net profit of $124 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
